Neurofilament Light Chain (NfL): The Blood Test That May Track Nerve Damage

The blood test I want to tell you about today has a mouthful of a name — neurofilament light chain — and it might just change how doctors talk about nerve damage in the next few years. It won't diagnose your neuropathy on its own. It won't tell you which nerve is hurting or why. But it can, in the right situation, do something quite remarkable: it can tell you whether your nerves are being actively injured right now, or whether things have stabilized.

That is new. And for those of us who have spent years wondering “is this getting worse, or am I just having a bad week?” — a blood test that can help answer that question is a genuinely big deal.

Let me walk you through what neurofilament light chain (NfL for short) actually is, what the test can and can't tell you, when it might be worth asking about, and what the honest 2026 status is regarding availability and cost.

What Neurofilament Light Chain Actually Is

Every axon in your body — the long fiber part of a nerve cell that carries signals down your leg or arm — is held together by internal scaffolding. That scaffolding is built out of three related proteins called neurofilaments. The lightest of the three is neurofilament light chain, or NfL.

Under normal conditions, NfL stays inside the axon where it belongs. When an axon is damaged, ruptured, or actively dying, NfL leaks out. It moves from the injured axon into the surrounding tissue fluid, drifts into the spinal fluid, and eventually reaches the bloodstream, where it can be measured.

The trouble was, until fairly recently, we didn't have a blood test sensitive enough to detect NfL in the tiny amounts that circulate. NfL is not abundant — we're talking about levels of picograms per milliliter, which is a billionth of a gram in a fifth of a teaspoon. A newer technology called Simoa (single-molecule array) changed that around 2010 by making it possible to detect single protein molecules, one at a time.

That's when the field exploded. Suddenly researchers could measure axonal damage from a routine blood draw instead of from a spinal tap. Studies started pouring out. NfL turned out to be elevated in an astonishing number of neurological conditions.

The Diseases Where NfL Has Been Useful So Far

Most of the early NfL research was in central nervous system diseases — multiple sclerosis, ALS, dementia, traumatic brain injury, stroke. In MS in particular, NfL has become a standard tool used to monitor disease activity and guide treatment decisions. The FDA cleared a commercial NfL blood test for MS in 2025.

What's newer, and what matters most for our community, is the growing body of evidence that NfL is also useful for tracking peripheral nerve damage — the nerves in the arms, legs, hands, and feet that neuropathy affects.

Recent studies have looked at NfL levels in:

• Diabetic peripheral neuropathy — a January 2026 study found that combining NfL with another marker (Tau) achieved 93.9% sensitivity and 82.4% specificity for identifying diabetic neuropathy.
• Chemotherapy-induced peripheral neuropathy (CIPN), particularly from paclitaxel — where NfL levels predict and track the severity of nerve damage.
• Vasculitic neuropathy — where NfL correlates with the actual damage seen on nerve biopsies. See our overview of small fiber neuropathy for context on why this matters.
• Systemic amyloidosis — where NfL rises with nerve involvement and can drop with successful treatment.
• CIDP and Guillain-Barré syndrome — where NfL is elevated during the acute phase and can help track recovery.

The Most Important Thing to Understand About NfL

Before I say anything else about this test, I need to say the thing I wish more articles would lead with:

NfL is not disease-specific. It measures axonal damage of any kind, from any cause.

That single sentence explains most of the confusion about this test. NfL can be elevated by MS. By dementia. By a recent concussion. By your peripheral neuropathy. By an old stroke. Sometimes by all of those at once. The test can tell you that some axons somewhere in your nervous system are being damaged. It cannot, by itself, tell you which ones or why.

That's why NfL is a monitoring and tracking tool, not a diagnostic tool. It's most valuable in a person whose diagnosis is already known — where the question is how active is the disease right now — not in a person walking in with unexplained numbness who is hoping for a definitive answer.

When NfL Testing Actually Helps

There are several situations where I've seen NfL testing meaningfully change decisions:

Tracking response to treatment. If you're on IVIG for CIDP, or rituximab for anti-MAG neuropathy, or a chemotherapy regimen that's neurotoxic, a falling NfL is real-time evidence that things are moving in the right direction. A rising NfL despite treatment is a signal to change course.

Deciding whether to escalate. When someone has stable symptoms but their doctors are wondering whether to add a stronger medication, an elevated NfL can push toward action. A normal NfL can support watchful waiting.

Prognostic clarity. In amyloidosis, in particular, higher baseline NfL levels have been associated with worse long-term outcomes. That information can shape decisions about how aggressive to be with treatments that carry their own risks.

Chemotherapy monitoring. As NfL testing becomes more common, some oncology practices are exploring using it to catch chemo-induced nerve damage earlier, before symptoms become disabling. The evidence base is still being built here, but it's promising. See our guide on chemo-induced neuropathy for background.

When NfL Testing Won't Help Much

I want to be equally honest about the situations where NfL isn't the right tool:

For most people with garden-variety, well-controlled diabetic neuropathy. Your feet hurt, your doctor knows it, you're managing your blood sugar, you're on a medication or two. NfL won't change the plan.

As a screening test. If you have no neurological symptoms and no known disease, an elevated NfL will confuse more than it clarifies. It can just as easily reflect aging or an old event as a current problem.

For localized nerve entrapments — carpal tunnel, tarsal tunnel, meralgia paresthetica. NfL is a systemic marker; it doesn't spike much from a single pinched nerve.

For symptoms without clear axonal damage. Some forms of neuropathy involve small nerve fibers or the myelin sheath (the insulation around nerves) without much axon injury. NfL may not be elevated in those cases.

What Actually Happens When You Get the Test

It's a straightforward blood draw. No special preparation needed. The tube goes off to a specialty lab (Labcorp offers it as test 140455; Quest, Mayo Clinic Labs, and ARUP also offer it). Results typically come back within a week or two.

You'll get a number in picograms per milliliter (pg/mL). And here's where it gets tricky.

Why the Number Alone Doesn't Tell You Much

Age matters enormously for NfL. A healthy 30-year-old might have an NfL of 5 pg/mL. A healthy 75-year-old might have 20 pg/mL, with no disease at all. The reference ranges published by labs try to account for this, but they vary between labs.

BMI matters too. Higher BMI is associated with lower measured NfL, likely because the same amount of NfL is diluted in more blood volume. Kidney function matters — impaired kidneys clear NfL more slowly, raising the measured level.

So an interpretation like “your NfL is 22 pg/mL, that's high” is only meaningful if you also know your age, your BMI, your kidney function, and how those factors are weighted in the lab's reference range.

Ideally, NfL is most useful as a trend, not a single value. Your NfL last spring compared to your NfL today tells a story that a single measurement can't. That's why the most valuable use of NfL testing is often serial testing over months, not a one-off snapshot.

Cost and Insurance Reality in 2026

NfL testing is available commercially, but insurance coverage is uneven. Some insurers cover it for MS monitoring, where the clinical evidence is strongest. Coverage for peripheral neuropathy monitoring is much spottier.

Out-of-pocket, the test typically runs in the $150-$400 range depending on the lab and geography. Some large academic centers run their own version at lower cost when the test is ordered as part of a neurology workup.

If your doctor thinks NfL testing would meaningfully change your care, it's worth asking whether pre-authorization is possible. The strongest coverage cases are for CIDP monitoring, amyloidosis follow-up, and chemotherapy-related neuropathy tracking.

How to Ask Your Doctor About It

If you're wondering whether NfL testing makes sense for you, here's the conversation I'd suggest.

First, frame it around a decision. Not “is my neuropathy getting worse in general” — that's too broad. Something more like: “I'm having a hard time telling whether my symptoms are stable or progressing. Would an NfL test help you decide whether to change my treatment plan?”

Second, be prepared for a “no.” Most primary care doctors and even many general neurologists don't routinely use NfL for peripheral neuropathy monitoring yet. It's still primarily used at academic medical centers, in specialty neurology clinics (particularly neuromuscular clinics), and in patients with active autoimmune or amyloid conditions. That doesn't mean the test is wrong for you — it may just mean you need a specialist referral to access it thoughtfully.

Third, if you do get the test, ask specifically for the interpretation. Not just “here's your number.” Ask: does this number, given my age and BMI, suggest active axonal damage? If we retest in six months, what change would you consider significant?

For a broader look at what tests your neurologist might order, our guide to neuropathy diagnosis walks through the more traditional workup.

What NfL Doesn't Replace

I want to be clear: NfL doesn't replace the tests you probably already know. It's an addition to the toolkit, not a substitute.

Nerve conduction studies and EMG still tell us about the electrical function of specific nerves. Skin biopsy still tells us about small fiber density. Blood work for B12, HbA1c, thyroid function, and inflammatory markers still tells us about underlying causes. Imaging (MRI, ultrasound) still shows structural problems.

What NfL adds is a real-time “is damage happening right now” signal that none of those other tests provide. EMG shows you the current state of your nerves. Skin biopsy shows you what's there today. NfL shows you the direction the wind is blowing.

The Bigger Story NfL Is Part Of

The reason I'm writing about NfL now, in mid-2026, is that it's part of a much bigger shift happening in how nerve disease gets managed. For most of medical history, we've had two ways to know about a nerve problem: what the patient tells us, and what a physical exam or nerve conduction study shows.

Both of those have huge blind spots. Symptoms can be vague or hard to describe. Nerve conduction studies test only large nerves, in specific places, at a moment in time.

Blood-based biomarkers like NfL are the beginning of something different — a way to monitor nerve health continuously, cheaply, and quantitatively. Combined with other emerging markers (like plasma pTau or specific inflammatory signals), we may be moving toward a future where a routine blood panel tells your neurologist as much about the state of your nerves as an EMG tells them today.

That future is not here yet. NfL is a first-generation biomarker with real limitations. But it's a genuine step forward, and it's already changing how the best neuromuscular clinics manage complex cases.

What I Hope Comes Next

The dream, honestly, is a nerve-specific biomarker — something that leaks out of peripheral nerves in particular and doesn't just reflect any-neuron-anywhere damage. That would let doctors distinguish central from peripheral nervous system disease from a blood test, and let people like us know whether the numbers reflect our neuropathy specifically or something else going on.

Research groups are working on this. Some are looking at post-translationally modified NfL fragments that may be more specific to peripheral nerves. Others are looking at entirely different proteins that are enriched in peripheral axons. None of this is clinically available yet, but the science is active and the potential is real.

In the meantime, NfL is what we have — an imperfect but genuinely informative window into what your nerves are doing between doctor's visits. It's not a magic wand. But knowing what it is, when to ask about it, and what to make of the number when you get it is worth having in your back pocket the next time you or a family member navigates a complex neuropathy question.

Frequently Asked Questions

Can I ask my primary care doctor to order NfL?
You can ask, but many primary care doctors haven't used NfL clinically yet and may not feel comfortable ordering or interpreting it. In practice, NfL is most reliably accessed through a neurologist, especially one with neuromuscular specialty training. If your primary care doctor is open to it, they can absolutely order the test through Labcorp or Quest.

Does insurance cover NfL testing for neuropathy?
Coverage is inconsistent. Insurance is more likely to cover NfL for multiple sclerosis monitoring, CIDP, and amyloidosis. Coverage for general peripheral neuropathy monitoring is patchy. Out-of-pocket cost typically runs $150 to $400. Pre-authorization from your insurer, with a clear clinical justification from your doctor, gives the best chance of coverage.

How often can I have it repeated?
There's no universally accepted testing interval. In active disease, every three to six months is common. In stable disease, annual testing may be enough. The value comes from having a baseline and then watching the trend.

What does a normal number mean if I still have neuropathy symptoms?
A normal NfL doesn't rule out neuropathy. It suggests axonal damage isn't happening at high rates right now. Your symptoms may reflect established, stable nerve damage that isn't currently getting worse, or they may reflect small-fiber or myelin-related problems that NfL doesn't capture well.

Can NfL tell me whether my nerves are recovering?
Sometimes. A falling NfL over time, especially in the context of treatment for an active nerve condition, suggests reduced ongoing damage. It doesn't directly measure regeneration, but less new damage combined with the body's natural repair processes is broadly a good sign.

Is a high NfL always a bad sign?
Not always. It can reflect recent damage that's already stabilized, an unrelated neurological event, aging, or kidney issues affecting clearance. Context is everything. A single high number should trigger conversation with your doctor, not panic.

Is NfL the same as the test they use in MS?
Yes — it's the same molecule and often the same test. Reference values and interpretation differ somewhat depending on the disease context, but the underlying blood test is the same one used to monitor MS activity.

Neurology is quietly getting better at seeing what's happening inside your nerves without cutting anyone open or hooking anyone up to a machine. NfL is one of the first tests to demonstrate that shift. It won't answer every question. But if your care team knows how to use it, it can turn some of the “we'll just have to see” moments into “here's what we're seeing, and here's what we're going to do about it.” That's progress.

About the Author

View All Posts